Ischaemia-reperfusion (IR) injury is a recognized cause of perioperative morbidity and mortality affecting a wide range of surgical procedures, but particularly cardiovascular surgery. Over the past 30 years a large body of published animal and clinical research has suggested that ischaemic preconditioning (IPC), consisting of a limited ischaemic insult applied before the expected major ischaemic insult, can reduce the extent of IR injury, and protect the heart, lungs, kidney, liver and other vulnerable organs.
However, in 2015 two large multicentre, double-blind randomized clinical trials (Effect of Remote Ischaemic preConditioning on clinical outcomes in patients undergoing Coronary Artery Bypass Graft surgery, ERICCA; Remote Ischaemic Preconditioning for Heart Surgery, RIPHeart) 1,2 of remote IPC (RIPC) in cardiac surgery were published that reported no significant clinical benefit in the preconditioning arm. A subsequent editorial by Zaugg and Luchinetti 3 cast doubt not only on the efficacy of RIPC but also its safety, as the ERICCA trial reported that the rate of death and fatal myocardial infarction was greater in the preconditioned arm, although the overall incidence of myocardial infarction was lower. A similar effect was reported in the RIPHeart trial, although neither observation reached statistical significance.
Invited participants in the subsequent online discussion struggled to explain why the benefits of preconditioning, so consistently demonstrated in laboratory animal studies, proved so difficult to replicate in real-world clinical situations 4 . As the discussion progressed it became apparent that certain methodological issues had potentially affected both trials. By re-examining these, in the light of the original animal studies, useful insights could be provided for the conduct of further research and the design of future trials.
In this issue of the BJS, Orci and colleagues 5 demonstrate the potential benefit of IPC in a murine model of steatotic liver disease and speculate on the potential clinical applications in patients undergoing liver surgery. This justification is similar to that used in the initial animal studies of cardiac preconditioning performed some three decades ago, but which failed to be realized in the ERICCA and RIPHeart trials. So what are the potential difficulties in translating animal studies into human clinical practice? To explore this question, it is useful to re-examine the original research and reinterpret the results in the light of these subsequent clinical trials.
In some of the original canine research one group of dogs, subjected to four 5-min cycles of clamping and reperfusion of the circumflex coronary artery before 40 min of occlusion, had significantly smaller areas of myocardial infarct than a group who had just the 40-min occlusion 6 . However, this beneficial effect disappeared when both groups were subjected to 3 h of coronary occlusion 6 . The two important points here were that infarct size was reduced by preconditioning rather than avoided, and that if the ischaemic insult was large enough the protective effect of IPC was overwhelmed. Therefore, studies that look purely for binary outcomes, for example infarct or not, may miss some of the beneficial effects of IPC. Second, IPC is likely to protect a patient only from moderate harm, that is the IR injury associated with routine performance of the procedure. If the operation is complicated (the anastomosis disintegrates, the bypass graft occludes), the insult may become too great for IPC to prevent serious injury or death.
Subsequent animal studies identified that the protective effect of IPC occurs in two phases: early and late 7 . The early-phase protection is greatest during the first hour after the preconditioning stimulus and, although the exact mechanism remains to be determined, it is thought to be mediated via various neurohumoral factors. The beneficial effect decreases after this time and is abolished completely within a few hours, only to return in diminished form after 24 h (late phase), which is postulated to be due to altered gene expression 7 . Therefore, the timing of the IPC stimulus in relation to the ischaemic insult is important; if it is delayed beyond the hour, early-phase protection may be attenuated or lost.
Early studies concentrated on direct IPC, applying the preconditioning stimulus directly to the target organ, which limits clinical value to interventions that have surgical access to the organ to be protected. The discovery that brief periods of skeletal muscle ischaemia provided IPC protection to the heart and other distant organs increased the potential range of interventions 8 . Once again the technique proved more reliable in animal laboratory studies than human trials, but sufficient positive results were obtained in smaller human studies to justify larger multicentre trials. Various RIPC regimens and techniques have been used, ranging from applying a pressure cuff to a single arm to direct sequential clamping of both iliac arteries 9 . The approach has been somewhat pragmatic, and the amount of skeletal muscle mass necessary to provide RIPC protection in any given clinical situation, or whether the amount of muscle mass is important, is yet to be determined.
Preconditioning seems particularly suited to surgical application because the timing of the IR insult can be predicted. Postconditioning is the application of the IPC stimulus after the IR injury and has been proposed for use after unpredictable episodes of ischaemia, or in combination with preconditioning to augment the protective effect 10 . To date, preconditioning has been applied to a greater number of clinical indications than postconditioning.
In animal studies most experiments are performed in small animals with different metabolic rates from humans and in carefully controlled experimental environments. The IPC stimulus and IR injury can be applied consistently using accurate timing intervals in animals who have a similar body mass and lack of co-morbidities and medications 4 .
In the ERICCA and RIPHeart trials, as in most clinical studies, variables included pre-existing cardiac ischaemia, co-morbidities, co-medications, differing levels of disease, sex and bodyweight variables, and variable times from RIPC stimulus to IR injury 1,2 . Patients were randomized to coronary artery surgery with, or without heart valve surgery, and there was no restriction on the number of coronary artery bypasses performed. The RIPC stimulus consisted of four 5-min cycles of single-arm blood pressure cuff inflation and deflation, applied after induction of anaesthesia but before surgical incision. Sham RIPC was performed in the control group. Both trials used standard cardiopulmonary bypass. ERICCA specified the use of blood cardioplegia, but not the method of administration or the composition of the solution. RIPHeart did not specify blood cardioplegia and neither trial commented on temperature control. The anaesthetic technique in the ERICCA trial used a combination of propofol infusion with, or without volatile anaesthetic, whereas RIPHeart used propofol infusion only.
From these limited details it is apparent that considerable differences exist between standard animal and clinical studies: cardiopulmonary bypass and blood cardioplegia have seldom featured in animal studies. Most significantly, commonly used anaesthetic agents may potentiate or interfere with the preconditioning response. As Zaugg and Luchinetti 3 pointed out, the anaesthetic agent propofol, used predominantly in the RIPHeart study and in nearly 90 per cent of the patients in ERICCA, is known to diminish or even ablate the effects of RIPC, whereas volatile anaesthetic agents may have variable effects.
Participants in the online discussion commented that if RIPC were a drug it would be one for which the effective dose, timing and pharmacokinetics are unknown. Were the four cycles of single-arm preconditioning used in the ERICCA and RIPHeart trials adequate to produce a RIPC stimulus sufficient to survive the anaesthetic, cardiopulmonary bypass, cardioplegia, variable clamp times and patient co-morbidities?
After over 30 years of research into RIPC, it has taken the results of these two negative trials to bring the key issues of this potentially valuable technique into focus. In the future it is likely that the design of experiments will have to reflect more accurately the clinical scenario for which it is proposed, including commonly applied anaesthetic and surgical techniques and perioperative management.
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